ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2021

Abstract Number: 0070

Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

Zeynep Belce Erton1, Ecem Sevim2, Guilherme Ramires de Jesus3, Ricard Cervera4, Lanlan Ji5, Vittorio Pengo6, Amaia Ugarte7, Danieli Andrade8, Laura Andreoli9, Tatsuya Atsumi10, Paul R Fortin11, Maria Gerosa12, Yu Zuo13, Michelle Petri14, Savino Sciascia15, Maria Tektonidou16, Maria Angeles Aguirre17, D. Ware Branch18, Doruk Erkan1 and on Behalf of APS ACTION1, 1Hospital for Special Surgery, New York, NY, 2Montefiore Medical Center - Wakefield Campus, Bronx, NY, 3Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 4Hospital Clinic Barcelona, Barcelona, Spain, 5Peking University First Hospital, Beijing, China (People's Republic), 6Padova University Hospital, Padova, Italy, 7Hospital Universitario Cruces, Barakaldo, Spain, 8Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 9University of Brescia, Brescia, Italy, 10Hokkaido University, Sapporo, Japan, 11CHU de Quebec - Universite Laval, Québec City, QC, Canada, 12University of Milan, Milan, Italy, 13University of Michigan, Ann Arbor, MI, 14Johns Hopkins University School of Medicine, Baltimore, MD, 15University of Turin, Turin, Italy, 16FORZAFORTE HELLAS LTD, Athens, Greece, 17IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, 18University of Utah, Salt Lake City, UT

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2021

Keywords: antiphospholipid syndrome, pregnancy

Session Information

Date: Saturday, November 6, 2021

Title: Antiphospholipid Syndrome Poster (0069–0083)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL) positive patients with or without systemic autoimmune diseases. The objective of this analysis was to describe the new pregnancy outcomes of the aPL-positive patients since the inception of the registry.

Methods: A web-based data capture system is used to store patient demographics, history, and medications. The inclusion criteria are positive aPL according to Updated Sapporo Classification Criteria tested within one year prior to enrollment. Patients are followed every 12±3 months with clinical data and blood collection. We identified patients recorded as “pregnant” during prospective follow-up; new “aPL-related composite pregnancy morbidity” was defined as: a) preterm live birth (PTLB) at or before 37th week due to (pre)eclampsia (PEC) and/or small-for-gestational age (SGA); and b) fetal death (FD) after the 10th week. In addition to descriptive characteristics, we analyzed pregnancy outcomes based on different aPL-related histories.

Results: Since the inception of the registry in 2012, 77 completed pregnancies were recorded in 55 patients (mean maternal age: 33.4 ± 5.2y; primary aPL/APS: 41 [75%]; and SLE: 14 [25%]) (Table 1). Of 55 patients, 15 (27%) did not fulfill the clinical APS classification criteria, 8 (15%) had obstetric APS (OAPS) only, 18 (33%) thrombotic APS (TAPS) only, and 14 (25%) both OAPS+TAPS. Pregnancy outcomes are reported in Table 1. Sixty-seven of 77 (87%) pregnancies were treated with low dose aspirin (LDA) and/or low-molecular weight heparin (LMWH) (54 with LDA+LMWH): 9/77 (12%) were due to OAPS only (LDA+LMWH: 7); 21/77 (27%) TAPS only (LDA+LMWH: 18); 21/77 (27%) OAPS and TAPS (LDA+LMWH: 19); and 16/77 (21%) despite no APS classification (LDA+LMWH: 10). Table 2 demonstrates TLB, PTLB, FD, and PELS rates based on the history of thrombotic APS (vs not), obstetric APS (vs not), and APS (vs not); 93% of all patients were lupus anticoagulant [LA] positive (as well as 100% of those who developed aPL-related composite pregnancy morbidity).

Conclusion: In our multi-center international prospective aPL-positive cohort, of 77 pregnancies in 55 patients observed prospectively, 20 (26%) were complicated by (pre)embryonic losses. Of the remaining 57 pregnancies, aPL-related composite pregnancy morbidity was observed in 16/57 (28%) of pregnancies including 7/57 (12%) pre-term live births with SGA and/or PEC, and 9/57 (16%) fetal deaths.


Disclosures: Z. Erton, None; E. Sevim, None; G. de Jesus, None; R. Cervera, None; L. Ji, None; V. Pengo, None; A. Ugarte, None; D. Andrade, None; L. Andreoli, None; T. Atsumi, Takeda Pharmaceutical CO., Ltd., 6, Astellas Pharma Inc., 5, 6, Mitsubishi Tanabe Pharma Co., 5, 6, Chugai Pharmaceutical Co., Ltd., 5, 6, Daichii Sankyo Co. Ltd., 5, 6, Pfizer Inc., 2, 5, 6, Alexion Inc., 6, TEIJIN PHARMA LIMITED., 5, 6, Novartis Pharma K.K., 2, 5, 6, Eli Lilly Japan K.K., 5, 6, Kyowa Kirin Co., Ltd., 5, 6, AbbVie Inc., 2, 5, 6, NIPPON SHINYAKU CO.,LTD., 5, TAIHO PHARMACEUTICAL CO.,LTD., 5, Nippon Boehringer Ingelheim Co.,Ltd., 5, 6, Amgen Inc., 5, 6, UCB Japan Co. Ltd., 5, 6, Astra Zeneca plc, 2, 6, ONO Pharmaceutical Co., Ltd., 2, 5, Byaer Yakuhin, Ltd., 5; P. Fortin, Lilly, 1, AbbVie, 1, AstraZeneca, 1; M. Gerosa, None; Y. Zuo, None; M. Petri, Alexion, 1, Amgen, 1, Astrazeneca, 1, 5, Aurinia, 5, 6, Eli Lilly, 5, Emergent Biosolutions, 1, Exagen, 5, Gilead Biosciences, 2, GSK, 1, 5, IQVIA, 1, Idorsia Pharmaceuticals, 2, Janssen, 1, 5, Merck EMD Serono, 1, Momenta Pharmaceuticals, 2, PPD Development, 1, Sanofi, 2, Thermofisher, 5, UCB Pharmaceuticals, 2; S. Sciascia, None; M. Tektonidou, None; M. Aguirre, None; D. Branch, UCB Pharmaceuticals, 1, 5; D. Erkan, ACR/EULAR, 5, LCTC, 5, NIH/NIAID, 5, GSK, 5, 6, Exagen, 5, Alexion, 2, UCB, 2, UpToDate, 9, APS ACTION, 4; o. APS ACTION, None.

To cite this abstract in AMA style:

Erton Z, Sevim E, de Jesus G, Cervera R, Ji L, Pengo V, Ugarte A, Andrade D, Andreoli L, Atsumi T, Fortin P, Gerosa M, Zuo Y, Petri M, Sciascia S, Tektonidou M, Aguirre M, Branch D, Erkan D, APS ACTION o. Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/pregnancy-outcomes-of-antiphospholipid-antibody-positive-patients-prospective-results-from-antiphospholipid-syndrome-alliance-for-clinical-trials-and-international-networking-aps-action-clinical-da-2/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pregnancy-outcomes-of-antiphospholipid-antibody-positive-patients-prospective-results-from-antiphospholipid-syndrome-alliance-for-clinical-trials-and-international-networking-aps-action-clinical-da-2/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology